SCHEMBL2347876

SCHEMBL2347876

COc1ccc(C(OC)C(=O)O)c(F)c1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 5/20 0.45
PTGS1 P23219 4/20 0.45
CPS1 P31327 4/20 0.44
AKR1C3 P42330 4/20 0.43
AKR1C2 P52895 4/20 0.43
CDC42 P60953 1/20 0.43
RAC1 P63000 1/20 0.43
CYP1A2 P05177 1/20 0.43
TSHR P16473 1/20 0.43
SLC22A6 Q4U2R8 1/20 0.43
APP P05067 1/20 0.43
CYP2C19 P33261 1/20 0.43
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
KIF11 P52732 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2349189 0.87 AKR1C3 (0.43) PTGS2PTGS1CPS1AKR1C3AKR1C2
SCHEMBL5042623 0.85 FFAR1 (0.43) PTGS2PTGS1CPS1AKR1C3AKR1C2
SCHEMBL5041143 0.85 FFAR1 (0.43) PTGS2PTGS1CPS1AKR1C3AKR1C2
SCHEMBL9862302 0.82 CA12 (0.46) PTGS2PTGS1AKR1C3AKR1C2CDC42
SCHEMBL5037803 0.82 NPC1 (0.50) PTGS2PTGS1AKR1C3AKR1C2CDC42
SCHEMBL25379205 0.82 PTGS2 (0.46) PTGS2PTGS1CPS1AKR1C3AKR1C2
SCHEMBL10318257 0.82 PTGS2 (0.46) PTGS2PTGS1CPS1AKR1C3AKR1C2
SCHEMBL10318321 0.82 PTGS2 (0.46) PTGS2PTGS1CPS1AKR1C3AKR1C2
SCHEMBL5040984 0.82 MIF (0.39) PTGS2PTGS1AKR1C3AKR1C2CYP1A2
SCHEMBL1506644 0.82 PTGS2 (0.63) PTGS2PTGS1AKR1C3AKR1C2CDC42

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2222645-B1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS HOFFMANN LA ROCHE (CH) 2013-03-20 EP disclosed
US-8008503-B2 Methyl-benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2011-08-30 US disclosed
US-20100331371-A1 METHYL-BENZIMIDAZOLE DERIVATIVES BENSON GREGORY MARTIN 2010-12-30 US disclosed
US-7825258-B2 Methyl-benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2010-11-02 US disclosed
US-20090131482-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-05-21 US disclosed
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 PTGS2 3734/4885PTGS1 1064/4885CPS1 2488/4885
US-20090131482-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HDAC10, CYP3A4, ECI1 PTGS2 1040/4885PTGS1 576/4885CPS1 290/4885
US-20100331371-A1 METHYL-BENZIMIDAZOLE DERIVATIVES HDAC10, CYP3A4, ECI1 PTGS2 1040/4885PTGS1 576/4885CPS1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.